Outcome of Aflibercept Intravitreal Injection in Vitrectomiz
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to evaluate the efficacy of intravitreal Aflibercept injection (IAI) for vitrectomized eyes with diabetic macular edema (DME) at one year.

This study includes diabetic patients with a HbA1c of less than 9%, visual acuity of 20/400 to 20/40 attributable to DME, and vitrectomy for at least 3 months prior to the first aflibercept injection. For the first year of treatment, patients received 5 monthly aflibercept injections accompanied by a ProReNata regimen. At 6 months and 1 year, visual acuity, OCT observations, and the number of IAI were evaluated.

--46 eyes were included. Indications for vitrectomy were epiretinal membrane (58.7%), intravitreal hemorrhage (26.1%), and vitreomacular traction (8.7%), retinal detachment (4.3%), and other cause (4.3%).

--Median duration of macular edema was 3 years. Median interval between vitrectomy and first visit was 9 months.

--30 eyes were non-naive and received previously thermal laser (44.3%), intravitreal injection of triamcinolone (26.7%), of ranibizumab (70%), of dexamethasone implant (36.7%), or bevacizumab (6.7%).

--Data was available for 35 eyes at 1 year. Visual gain was significant, +6 letters and central subfield thickness (CST) decreased significantly (? 108 micrometre) at 1 year.

--Mean number of injections was 9.3 and mean interval injection was 5.8 weeks.

In conclusion, these findings indicate that IAI may be useful in vitrectomized eyes with refractory DME that require repeated injections to achieve visual and anatomical improvement.

Source: https://www.dovepress.com/one-year-outcome-of-aflibercept-intravitreal-injection-in-vitrectomize-peer-reviewed-fulltext-article-OPTH